Neumora TherapeuticsNMRA
NMRA
About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Employees: 96
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
148% more call options, than puts
Call options by funds: $134K | Put options by funds: $54K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
7% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 28
5.77% less ownership
Funds ownership: 40.27% [Q1] → 34.5% (-5.77%) [Q2]
16% less funds holding
Funds holding: 115 [Q1] → 97 (-18) [Q2]
37% less capital invested
Capital invested by funds: $65.2M [Q1] → $41M (-$24.3M) [Q2]
38% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 40
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
198%
upside
Avg. target
$5
198%
upside
High target
$5
198%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Mizuho Graig Suvannavejh | 198%upside $5 | Outperform Maintained | 16 Jul 2025 |
Financial journalist opinion
Based on 3 articles about NMRA published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Daljit Singh Aurora - Corporate Participant Chief Operationg & Development officer - Corporate Participant Helen Rubinstein - Head of Investor Relations Joshua Pinto - President Michael Lee Milligan - CFO & Principal Accounting Officer Nicholas Brandon - Chief Scientific Officer Paul L. Berns - Chairman & CEO Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division Douglas Dylan Tsao - H.C.
Positive
The Motley Fool
2 weeks ago
Neumora (NMRA) Q2 Loss Improves 10%
Neumora Therapeutics (NMRA -4.22%), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most significant news was a reduction in both research and development spending and overall net loss, while the company advanced multiple programs in its clinical pipeline.
Neutral
GlobeNewsWire
2 weeks ago
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with data from diet-induced obesity (DIO) mouse model expected in 2025 Entering catalyst-rich period with up to six clinical data readouts in patients over the next 18 months, including Phase 3 data for navacaprant in major depressive disorder (MDD) and Phase 1b data for NMRA-511 in Alzheimer's disease agitation Strong financial position with $217.6 million in cash, cash equivalents and marketable securities expected to support operations into 2027 Company to host conference call today at 4:30 p.m. ET WATERTOWN, Mass.
Neutral
GlobeNewsWire
1 month ago
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update.
Neutral
GlobeNewsWire
1 month ago
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-861 in healthy adult participants and adults with stable schizophrenia.
Neutral
GlobeNewsWire
2 months ago
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareholders.
Neutral
PRNewsWire
3 months ago
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
NEW YORK , May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Neumora Therapeutics caused the company to misrepresent or fail to disclose (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.
Neutral
Seeking Alpha
3 months ago
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q1 2025 Results Conference Call May 12, 2025 4:30 PM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Berns - Chief Executive Officer Josh Pinto - President Bill Aurora - Chief Operating & Development Officer Mike Milligan - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Yatin Suneja - Guggenheim Graig Suvannavejh - Mizuho Securities John Boyle - William Blair Operator Ladies and gentlemen, thank you for standing by.
Neutral
GlobeNewsWire
3 months ago
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runway extended into 2027 Company to host conference call today at 4:30 p.m. ET WATERTOWN, Mass.
Neutral
GlobeNewsWire
3 months ago
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m.
Charts implemented using Lightweight Charts™